Literature DB >> 10892905

Oncogenic ras results in increased cell kill due to defective thermoprotection in lung cancer cells.

R A Vertrees1, J B Zwischenberger, P J Boor, S D Pencil.   

Abstract

BACKGROUND: The survival response of normal cells to heat stress is an upregulation of heat shock proteins and ras protein activation. We hypothesized that in lung cancer cells the presence of oncogenic ras interferes with thermoprotective mechanisms resulting in cell death.
METHODS: An equal number of lung tissue culture cells (normal and cancerous) were subjected to either heat stress and then recovery (43 degrees C for 180 minutes, 37 degrees C for 180 minutes) or recovery alone (37 degrees C for 360 minutes). End points were surviving number of cells, cell-death time course, heat shock protein (HSP70, HSC70, HSP27) expression before and after heat stress, and time course for HSP70 expression during heat stress and recovery. Heated cells were compared with unheated control cells, then this difference was compared between cell types.
RESULTS: Heat stress in normal cells caused an 8% decrease in cell number versus a 78% +/- 5% decrease in cancer cells (p < 0.05). In normal cells, heat stress caused a 4.4-fold increase in HSP70, no change in HSC70, and a 1.7-fold increase in HSP27. In contrast, cancer cells initially contained significantly less HSP70 (p < 0.05), and there was a 27-fold increase in HSP70 and a 2-fold increase in HSC70 with no HSP27 detected (comparison significant, p < 0.05). HSP70 time course in normal cells showed that HSP70 increased 100-fold, reaching a vertex at 2 hours and remaining elevated for 24 hours; in cancer cells, HSP70 maximum expression (100-fold) peaked at 5 hours,,then decreased to slightly elevated at 24 hours.
CONCLUSIONS: Cancer cells with oncogenic ras have defective thermoprotective mechanism(s) causing increased in vitro cell death, which provides an opportunity for thermal treatment of lung cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10892905     DOI: 10.1016/s0003-4975(00)01421-1

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

1.  Physical limits of cells and proteomes.

Authors:  Ken A Dill; Kingshuk Ghosh; Jeremy D Schmit
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

2.  Non-lethal heat treatment of cells results in reduction of tumor initiation and metastatic potential.

Authors:  Yoo-Shin Kim; Tae Hoon Lee; Brian E O'Neill
Journal:  Biochem Biophys Res Commun       Date:  2015-05-29       Impact factor: 3.575

3.  Venovenous perfusion-induced systemic hyperthermia: five-day sheep survival studies.

Authors:  Cherry Ballard-Croft; Dongfang Wang; Kyle Rosenstein; Jingkun Wang; Robert Pollock; J Ann Morris; Joseph B Zwischenberger
Journal:  J Thorac Cardiovasc Surg       Date:  2014-05-05       Impact factor: 5.209

4.  Resolution of pulmonary hypertension complication during venovenous perfusion-induced systemic hyperthermia application.

Authors:  Cherry Ballard-Croft; Dongfang Wang; Cameron Jones; Jingkun Wang; Robert Pollock; Bob Jubak; Stephen Topaz; Joseph B Zwischenberger
Journal:  ASAIO J       Date:  2013 Jul-Aug       Impact factor: 2.872

5.  Cellular proteomes have broad distributions of protein stability.

Authors:  Kingshuk Ghosh; Ken Dill
Journal:  Biophys J       Date:  2010-12-15       Impact factor: 4.033

Review 6.  Molecular parameters of hyperthermia for radiosensitization.

Authors:  Tej K Pandita; Shruti Pandita; Sukesh R Bhaumik
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2009       Impact factor: 1.807

7.  A physical model of cell metabolism.

Authors:  Jorge Fernandez-de-Cossio-Diaz; Alexei Vazquez
Journal:  Sci Rep       Date:  2018-05-29       Impact factor: 4.379

8.  Cell mechanical properties of human breast carcinoma cells depend on temperature.

Authors:  Christian Aermes; Alexander Hayn; Tony Fischer; Claudia Tanja Mierke
Journal:  Sci Rep       Date:  2021-05-24       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.